CliffBio
small molecule

NEOSTIGMINE METHYLSULFATE

NEOSTIGMINE METHYLSULFATE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameNEOSTIGMINE METHYLSULFATE
Active ingredientNEOSTIGMINE METHYLSULFATE
Strength3MG/3ML (1MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalSeptember 2018
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.